1. Lymphoma refers to cancers that develop from lymphocytes, a type of white blood cell.
2. The document discusses the classification, signs and symptoms, diagnosis, and origins of several types of lymphoma including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma.
3. It also covers Hodgkin lymphoma, marginal zone lymphoma, mantle lymphoma, and hairy cell leukemia providing details on their clinical features and pathogenesis.
Actinic keratoses: Erythematous scaly lesions on sun-damaged skin & considered “precancerous” lesions that have the potential to progress into invasive SCC.
Bowen’s disease: SCC in situ It has the potential to progress to invasive SCC.
Leukoplakia: Leukoplakia refers to a white patch or plaque on the oral mucosa that cannot be wiped off and cannot be characterized clinically or pathologically as any other disease.
This PowerPoint presentation demonstrate a useful review of Oral candidiosis, including its different types, clinical presentations, differential diagnosis, and treatment options.
pathology of round cell tumours of osseo articular system like ewings sarcoma, mesenchymal chondrosarcoma,small cell osteosarcoma, plasma cell neoplasms and other hematopoietic malignancies. how immunochemistry os playing pivotal role in differential diagnosis.
NEOPLASMS AND PROLIFERATIONS OF FOLLICULAR LINEAGE
NEOPLASMS AND PROLIFERATIONS WITH SEBACEOUS DIFFERENTIATION
NEOPLASMS AND PROLIFERATIONS WITH APOCRINE DIFFERENTIATION
NEOPLASMS AND PROLIFERATIONS WITH ECCRINE DIFFERENTIATION
Actinic keratoses: Erythematous scaly lesions on sun-damaged skin & considered “precancerous” lesions that have the potential to progress into invasive SCC.
Bowen’s disease: SCC in situ It has the potential to progress to invasive SCC.
Leukoplakia: Leukoplakia refers to a white patch or plaque on the oral mucosa that cannot be wiped off and cannot be characterized clinically or pathologically as any other disease.
This PowerPoint presentation demonstrate a useful review of Oral candidiosis, including its different types, clinical presentations, differential diagnosis, and treatment options.
pathology of round cell tumours of osseo articular system like ewings sarcoma, mesenchymal chondrosarcoma,small cell osteosarcoma, plasma cell neoplasms and other hematopoietic malignancies. how immunochemistry os playing pivotal role in differential diagnosis.
NEOPLASMS AND PROLIFERATIONS OF FOLLICULAR LINEAGE
NEOPLASMS AND PROLIFERATIONS WITH SEBACEOUS DIFFERENTIATION
NEOPLASMS AND PROLIFERATIONS WITH APOCRINE DIFFERENTIATION
NEOPLASMS AND PROLIFERATIONS WITH ECCRINE DIFFERENTIATION
this is powerpoint presentation comprising of latest updates and theory of lymphoma and plasma cell dyscrasias WHO 2016. restricted to all lymphomaniacs.
Lymphoma is a cancer of lymphocytes. The most common place for abnormal lymphocytes is in lymph nodes (glands) particularly
under the arms, in the neck and in the groin.
Lymphoma is solid tumors of the immune system arising from cells of lymphoid tissues; lymphocytes, histiocytes, and reticulum cells. It can happen anywhere in the immune system, but usually in lymph nodes, spleen, marrow, and tonsils. Location and the behavior of lymphomas separate them from leukemia.The malignancy starts and restricted to lymphoid tissues and progress to involve the BM and appears in PB, at this stage it may be named, “lymphosarcoma cell leukemia.
it is my power point presentation of lymphoma for final year MBBS students,govt.medical college,kottayam
dr irshad ali k m
assistant professor,dept.of medicine,govt,medical college,kottayam
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
19. ·Willis (1948)
“… nowhere in pathology has a chaos of
names so clouded clear concepts as in
the subject of lymphoid tumors ….”
•Hopwood (1957)
“… the urge to classify is a fundamental
human instinct: like a predisposition to
sin, it accompanies us into the world at
birth and stays with us to the end …”
21. WHO Classification of lymphomas
At least 30 types of lymphoma are recognized
3 broad flavors
- B-cell lymphomas
Precursor (immature),
peripheral (“mature”)
- T-cell lymphomas
- Hodgkin lymphoma ( bona fide lymphoma)
~ 85% in North America and Europe are B-cell
· two types account for > 50% of lymphomas
- diffuse large B-cell lymphoma (~ 30 - 40%)
- follicular lymphomas (~ 25 - 30%)
·
28. Diagnosing lymphoid neoplasias
• T-cell markers
– CD3 mature T cells
– CD4 – helper T cell
– CD5 – T cell, small
subset of B cells
– CD8 – cytotoxic T cell
• B cell markers
– CD19 - mature B cell
– CD20 - mature B cell
– CD23 - activated
mature B cell
– CD10
– Bcl-6
29. Lymphoid leukemia versus lymphoma
Somewhat arbitrary, distinctions for
lymphoid neoplasias
Lymphoid leukemia presents with mainly
bone marrow and blood involvement
Lymphoma presents with nodal or
extranodal mass with minimal
blood/marrow involvement
Many diseases overlap or evolve from one
another
30. Signs and symptoms
Lymphoid leukemias present with signs and
symptoms related to bone marrow
involvement
Anemia, thrombocytopenia, leukopenia
Lymphomas present as nontender mass (>2
cm)
Extranodal- skin, GI tract, brain,
Fever, weight loss, night sweats (B-symptoms)
Patients may have any combination of the
above
31. Origin of B-cell lymphomas
Marginal zone
Mantle zone
Germinal center
Naive B-cell
Mantle cell
lymphoma
Follicular lymphoma
Burkitt lymphoma
Large cell lymphoma
Memory B-cell
CLL/SLL
Marginal zone
lymphoma
Plasma cell
Myeloma
32. Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma
CLINICAL
•commonest leukemia
•CLL often picked up on routine CBC
•typically indolent (but not always!)
•rare less than 40 years
•complications:
• autoimmune (10-15%) (ITP, AIHA)
• hypogammaglobulinemia
• transformation (DLBCL)
PATHOLOGY
•diffuse growth pattern
Spleen is frequently involved
37. FOLLICULAR LYMPHOMA
15-20 000/year, less common in Europe, Asia
-Middle age patient’s
-Most common indolent lymphoma
-Peripheral blood 10%
-Bone marrow 85% involved
-Spleen and liver also commonly involved
-Can undergo transformation into large cell lymphoma
38. Follicular lymphoma
Classic low power view
- back-to-back follicles
- loss of interfollicular
zones
- extranodal follicles
- uniform size of follicles
40. Follicular lymphoma
diagnostic hallmark t(14;18)
Translocates the bcl-2 gene
next to IgH
over expression of bcl-2 prevents
apoptosis
Bcl-2 +
Bcl-2 – staining in normal
Lymphoid follicle
45. Origin of B-cell lymphomas
Marginal zone
Mantle zone
Germinal center
Naive B-cell
Mantle cell
lymphoma
Follicular lymphoma
Burkitt lymphoma
Large cell lymphoma
Memory B-cell
CLL/SLL
Marginal zone
lymphoma
Plasma cell
Myeloma
CB/CC
46. Diffuse Large B-cell Lymphoma
Most common non Hodgkin lymphoma(~40%)
- 25, 000 new cases/year
- median age 6th decade - all age
groups
- typically present with a single rapidly
enlarging mass
- often (~ 40%) extranodal
Variable clinical outcome
aggressive, has to be treated immediately
47. Diffuse Large B-cell lymphoma
Etiology and clinicopathologic subtypes
- de novo
-BCL-6 mutation freezes the differentiation of cells in the
germinal center + blocks the effect of p53
-can occur anywhere in the body
- transformed from either follicular lymphoma (t14;18) or CLL/SLL
- immunosuppressed patients
- transplant patients, AIDS patients
- KSHV, EBV, HHV-8 infection
48. Diffuse Large B-cell Lymphoma
Note the population of large tumor cells, diffuse growth pattern, variation in size
and shape of cells, cells with vesicular nucleus and cleaved cells
49. Origin of B-cell lymphomas
Marginal zone
Mantle zone
Germinal center
Naive B-cell
Mantle cell
lymphoma
Follicular lymphoma
Burkitt lymphoma
Large cell lymphoma
Memory B-cell
CLL/SLL
Marginal zone
lymphoma
Plasma cell
Myeloma
CB/CC
51. Extremely aggressive high grade lymphoma
T(8-14) activates c-myc oncogene
Endemic Non-endemic Immunodeficiency
children and young adults
Site Jaw/Facial Ileocecal area Systemic/non-CNS
EBV ~ 100% ~ 15-20% ~ 25%
BM not involved can be can be
Cure rate high high ?
Burkitt lymphoma
54. Burkitt lymphoma
small round cells in a “starry sky” pattern created by macrophages
engulfing cellular debris, mitoses
55. Clinically:
- typically presents in elderly males
- frequently extranodal:
- leukemic phase
- GI: lymphomatous polyposis
- much more aggressive than other
- poor response to conventional
chemotherapy
- median survival 3 - 4 years
Mantle cell lymphoma
57. Origin of B-cell lymphomas
Marginal zone
Mantle zone
Germinal center
Naive B-cell
Mantle cell
Lymphoma
CLL/SLL
Follicular lymphoma
Burkitt lymphoma
Large cell lymphoma
Memory B-cell
CLL/SLL
Marginal zone
lymphoma
4.Plasma cell
Myeloma
CC/CB
58. Extra-nodal marginal zone lymphoma,
MALToma
• Pathogenesis:
– Autoimmune disorders: thyroid(Hashimoto), salivary glands
(Sjogren)
– Chronic infection: stomach, lung, skin, conjunctiva
– Begins as a polycloncal reactive process, over time becomes a
monoclonal B cell lymphoma
– In stomach, highly associated with helicobacter pylori
• monocytoid B cells, plasma cells, germinal centers,
lymphoepithelial lesions
• Survival: indolent in early stages
• Cell of origin: marginal zone B cell
60. Origin of B-cell lymphomas
Marginal zone
Mantle zone
Germinal center
Naive B-cell
Mantle cell
lymphoma
Follicular lymphoma
Burkitt lymphoma
Large cell lymphoma
Memory B-cell
CLL/SLL
Marginal zone
lymphoma
4.Plasma cell
Myeloma
CC/CB
61. typically presents as:
- male in 6th decade
- splenomegaly
- no lymphadenopathy
- CBC:
- pancytopenia
- marked monocytopenia
•splenic disease:
- red pulp (unique )
Hairy cell leukemia
62. Hodgkin lymphoma
Incidence
- ~ 1% of all new cancers in USA
- ~ 7,500 new cases/year
- constant recent increase
Age
- bimodal age-curve (unique in
cancer)
- 15 - 35
- > 50
Sex
- M:F = ~ 4:3 (except nodular
sclerosis)
71. NS MC LD LR
Frequency ~70% ~20% <1% ~5%
Usual age 15-30 any/middle >50 any
middle
Clinically females abdominal advanced early
mediastinal splenic marrow stage
5yr survival ~80% ~60% ~30% ~90%
Hodgkin lymphoma features
72. Staging of HL
• I: Single LN region or extra-nodal site
• II: 2 or more LN regions on same side of diaphragm
• III: LN on both sides of diaphragm, may include spleen
• IV: Multiple or disseminated foci
• Further divided into absence (A) or presence (B) of fever,
night sweats, unexplained weight loss of >10% body
weight